Translational Research
The Elman Research Group, led by Dr. Noel Elman, focuses on the investigation and development of the next generation of biomedical devices based on the synergy of MOEMS (Micro-Opto-Electro-Mechanical-Systems), bionanotechnology and novel biomaterials, with the specific purpose of enhancing current diagnostic and therapeutic methods for chronic illnesses and acute conditions. Our research group is clinically driven and operates as a technology incubator that addresses specific clinical needs for both civilian and military settings. The use of micro- and nano-systems is leveraged to create scalable devices that can be seamlessly integrated within the existing medical protocols.
The combined use of these technologies will allow more efficacious and less invasive diagnoses and treatments. The development of such innovative biomedical devices is aimed for a wide variety of pathologies, for which miniaturized systems will be developed as implantable or wearable devices for minimally invasive procedures and point-of-care applications.
The goal is for these revolutionary biomedical devices to become a seamless part of our healthcare system for preventive care and treatment, significantly improving our life expectancy and quality of life. Furthermore, we hope to rapidly transfer these technological platforms to the market in order to address highly prevalent diseases. Our group therefore develops technologies from identifying clinical need, idea conceptualization, design, simulations, fabrication, prototyping, lab testing, and regulatory process.
The combined use of these technologies will allow more efficacious and less invasive diagnoses and treatments. The development of such innovative biomedical devices is aimed for a wide variety of pathologies, for which miniaturized systems will be developed as implantable or wearable devices for minimally invasive procedures and point-of-care applications.
The goal is for these revolutionary biomedical devices to become a seamless part of our healthcare system for preventive care and treatment, significantly improving our life expectancy and quality of life. Furthermore, we hope to rapidly transfer these technological platforms to the market in order to address highly prevalent diseases. Our group therefore develops technologies from identifying clinical need, idea conceptualization, design, simulations, fabrication, prototyping, lab testing, and regulatory process.
Transitioning Cutting-Edge Technologies
